問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Linkou Chang Gung Medical Foundation

List

2449Cases

2021-10-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting2Sites

Terminated6Sites

2025-12-01 - 2027-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

2020-07-01 - 2026-06-30

Phase III

Completed
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)

  • Condition/Disease

    Eosinophilic Chronic Rhinosinusitis With Nasal Polyps

  • Test Drug

    肺昇朗/Fasenra

Participate Sites
6Sites

Recruiting6Sites

2021-05-01 - 2024-09-19

Phase II/III

Completed
A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for Up to 48 Weeks in Participants with Heart Failure with Left Ventricular Ejection Fraction > 40%

  • Condition/Disease

    Heart Failure

  • Test Drug

    AZD4831

Participate Sites
14Sites

Not yet recruiting1Sites

Recruiting11Sites

Terminated1Sites

Study ended1Sites

黃瑞仁
National Taiwan University Hospital

Division of Cardiovascular Diseases

2024-02-01 - 2026-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-01-01 - 2027-12-31

Phase III

Active
A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

  • Condition/Disease

    Gastric Cancer /Gastroesophageal Junction Cancer

  • Test Drug

    AZD0901

Participate Sites
7Sites

Recruiting7Sites

2022-09-15 - 2026-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2018-09-26 - 2022-05-18

Phase III

Active
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer.

  • Condition/Disease

    Locally Advanced or Metastatic Urothelial Cancer

  • Test Drug

    Durvalumab (MEDI4736)

Participate Sites
7Sites

Recruiting6Sites

蘇柏榮
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2023-10-01 - 2030-12-31

Phase III

Active
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01) Conditions

  • Condition/Disease

    Biliary Tract Cancer

  • Test Drug

    Rilvegostomig

Participate Sites
8Sites

Recruiting8Sites

2025-04-01 - 2030-06-18

Phase III

Active
A Phase III, Randomised, Open-Label, Sponsor-Blinded, Multicentre Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (ARTEMIDE-HCC01)

  • Condition/Disease

    Advanced Hepatocellular Carcinoma

  • Test Drug

    Rilvegostomig (AZD2936) Tremelimumab BEVACIZUMAB

Participate Sites
8Sites

Recruiting8Sites

1 26 27 28 29 30 245
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB